COFEPRIS and Regenerative Medicine in Mexico: How to Verify a Clinic

Why regulation matters before you book a flight

International patients exploring regenerative medicine in Mexico often arrive at the same question early in their research: who actually oversees these clinics, and how do I know the one I am considering is operating within the law? It is the right question to ask. Mexico has a real and structured regulatory system, and the agency at the center of it is COFEPRIS. Understanding how COFEPRIS works, what it covers, and how you can verify a clinic yourself is one of the most important pieces of due diligence you can do before any commitment. The principle is simple: a clinic that operates within a regulatory framework is a clinic that can be inspected, audited, and held accountable. A clinic that operates outside that framework cannot.

This guide is written for patients traveling from the United States, Canada, Europe, and elsewhere who want to understand the Mexican regulatory landscape in plain language, with practical steps for verifying a clinic and clear comparisons to the FDA and EMA frameworks they may already be familiar with.

What COFEPRIS is

COFEPRIS is the Comisión Federal para la Protección contra Riesgos Sanitarios, or in English, the Federal Commission for the Protection against Sanitary Risks. It is the federal health authority of Mexico, decentralized within the Secretaría de Salud (Ministry of Health), and its mandate is broad. It regulates medicines, medical devices, biological products, food, cosmetics, tobacco and alcohol, pesticides, occupational health risks, and the establishments that handle any of the above, including medical clinics, pharmacies, and laboratories. In short, COFEPRIS is to Mexico what the FDA is to the United States, with elements of what the EMA does in the European Union.

For regenerative medicine specifically, COFEPRIS is the authority that oversees the clinical establishment, the biological and pharmaceutical products used in treatments, the processing laboratories, and the medical advertising that clinics are allowed to publish. That is a wide perimeter, and it is the reason a clinic's COFEPRIS standing is the first item any serious patient should review.

The clinic itself: the COFEPRIS health notice

Every healthcare establishment in Mexico that provides medical services must file a sanitary notice, known as an Aviso de Funcionamiento or, more colloquially, an "aviso sanitario" (health notice). This notice is registered with COFEPRIS and identifies the legal entity, the address of the facility, the responsible health officer, and the scope of services provided. The notice becomes a permanent record on file with the federal authority, which retains the right to inspect the facility at any time.

A health notice is not a marketing badge. It is a legal filing that places the clinic inside the federal sanitary registry, makes its operations subject to inspection, and obliges it to comply with Mexican Official Standards (NOMs) covering infrastructure, clinical records, informed consent, pharmacovigilance, and waste management. A clinic that cannot produce a valid health notice is, by definition, operating outside the federal system. That is the single most important item to verify before any treatment.

At Regeneris Therapy, our COFEPRIS health notice number is 2323025036X00098, on file with the federal authority and listed publicly on our regulatory information page.

Biological products and cellular therapies

Regenerative medicine often involves biological products: cellular therapies, exosomes, platelet-rich plasma, growth factors, and related preparations. In Mexico, the regulatory treatment of these products depends on what they are and how they are processed.

For products manufactured at industrial scale and sold as commercial therapies, COFEPRIS requires sanitary registration under the categories defined in the General Health Law and its associated regulations on biological medicines. These registrations involve quality controls, pharmacovigilance obligations, and traceability from manufacturer to patient.

For autologous treatments processed at the point of care, including procedures such as platelet-rich plasma where the patient is both donor and recipient, the regulatory framework focuses on the clinical establishment, the qualifications of the treating physician, the laboratory standards in use, and the documentation of consent. The clinic itself must hold a valid health notice and operate under recognized clinical and laboratory standards.

For peptides and other compounded preparations, the relevant framework is *farmacia magistral*, discussed in the next section.

In all of these cases, the key principle is traceability. A regulated clinic can document where every biological product comes from, who processed it, and under what conditions. Vague reassurance is not documentation. Ask, and expect a clear answer.

The farmacia magistral framework

Many of the peptides and individualized preparations used in modern regenerative and longevity protocols are not industrially manufactured medicines with their own COFEPRIS sanitary registration. They are compounded for a specific patient based on a prescription, under what Mexican regulation calls a *farmacia magistral* model.

A *farmacia magistral* (master pharmacy) is a pharmacy authorized to compound preparations on a patient-specific basis. The framework is recognized under the Reglamento de Insumos para la Salud (Regulation of Health Inputs) and operationalized through specific provisions that allow compounding pharmacies to prepare formulations against a written prescription. The pharmacy itself must hold a COFEPRIS sanitary license, follow Good Compounding Practices, and document each preparation.

This framework is conceptually similar to the way 503A compounding pharmacies are regulated by the FDA in the United States, with a focus on patient-specific prescriptions, recognized standards of practice, and traceability of compounded preparations. It is the legal pathway that allows a physician in Mexico to prescribe individualized peptide therapies through a compounding pharmacy that operates within COFEPRIS oversight, and it is the framework patients should expect to see referenced when peptides are part of their protocol.

Medical advertising: the advertising notice

Mexico has specific rules about what clinics are allowed to communicate about medical services, especially when those services involve biological products or specialized therapies. Medical advertising is regulated, and clinics that promote their services to the public must file an advertising notice with COFEPRIS. This is separate from the operational health notice and covers the content and the channels of public communication.

The advertising notice is a meaningful safeguard. It places clinic communications under a regulatory expectation of accuracy and non-misleading content. A clinic that publishes outcome guarantees, dramatic before-and-after promises, or pricing that changes when you arrive is a clinic that does not respect the framework, regardless of what its website states. Our advertising notice number at Regeneris Therapy is 2323022002A00053, also on file with the federal authority.

How to verify a Mexican clinic yourself

You do not need to take any clinic's word for its regulatory status. Verification is available to the public, and a credible clinic will welcome the question rather than deflect it. The general steps are:

• Ask for the COFEPRIS notice numbers in writing. A clinic that operates within the system can produce the health notice number and the advertising notice number on request. If you receive vague language about "permits" without a specific number, treat that as a warning sign.
• Cross-check the clinic's legal name and address. The notice is filed against a specific legal entity at a specific address. Make sure they match what the clinic publishes about itself, including the name on its About page and the address on its contact information.
• Verify physician professional licenses. Every physician in Mexico holds a *cédula profesional* issued by the Ministry of Public Education (SEP) and verifiable in the public registry at cedulaprofesional.sep.gob.mx. This is independent of COFEPRIS and confirms that the physician is legally authorized to practice medicine in Mexico. Our medical team page lists the credentials of every physician on staff.
• Use the COFEPRIS citizen services portal. COFEPRIS maintains a public-facing Atención Ciudadana (Citizen Services) portal where individuals can submit inquiries or formal reports about regulated establishments. The same portal handles complaints, which means a clinic operating within the system understands it is accountable through a formal channel.
• Review the clinic's regulatory information page directly. A clinic that takes compliance seriously will publish its notice numbers, its health officer, its medical team credentials, and the applicable standards in a permanent, indexed page. You can review ours at /en/legal/regulatorio.

If a clinic resists any of these steps, the decision becomes simpler.

How COFEPRIS compares to the FDA and the EMA

International patients sometimes assume that regulation outside their home country is necessarily weaker or less developed. That is a misconception worth correcting. COFEPRIS is a federal regulatory authority recognized by the World Health Organization as a regional reference authority for medicines and biological products in the Americas, alongside major peer agencies. It participates in international harmonization efforts, including agreements with the FDA on data sharing and inspection cooperation.

In practice, the three systems share the same architectural principles. The FDA in the United States regulates medical products, devices, and the facilities that manufacture and dispense them, with separate authorities at the state level for clinical practice itself. The EMA in the European Union coordinates the centralized authorization of medicines across member states, while national agencies in each country handle clinic-level oversight. COFEPRIS in Mexico combines elements of both, with federal oversight of medical products and the establishments that provide healthcare services, plus the *cédula profesional* system at the SEP that regulates individual practitioners.

The systems differ in some specifics, including how cellular and regenerative therapies are categorized, what is approved as a commercial product versus what is delivered as part of medical practice, and how compounding pharmacies are regulated. But the foundational principle is the same in all three: regulation exists to protect patients, and an establishment operating within the framework is an establishment that can be held to a standard.

Why this protects you as an international patient

The practical reason regulation matters for someone traveling from abroad is that it gives you something concrete to verify before you board a plane. You do not need to interpret marketing language or evaluate clinical claims in isolation. You can ask for a notice number, check it against the public registry, and confirm that the clinic is on file with the federal authority. That single step removes a large portion of the risk associated with choosing a clinic in a country you have not visited before.

Regulation also gives you a path for after-care. Pharmacovigilance, the formal reporting of adverse reactions to biological products and medications, is part of the regulated framework in Mexico, and patients have a recognized channel for reporting any issue that arises during or after treatment. A clinic that operates within COFEPRIS oversight is a clinic with a defined responsibility to receive, document, and act on those reports, and to participate in the broader national surveillance system.

Finally, regulation supports informed consent. The Mexican Official Standards on clinical records and medical practice, including NOM-004-SSA3-2012, require written documentation of consent for relevant procedures and the maintenance of an individual clinical record for every patient. International patients should expect to sign clear consent documents, receive copies of their clinical record on request, and have a named treating physician identified before treatment begins. None of that is optional.

What to ask a Mexican clinic before booking

To summarize the practical checklist for international patients:

• Ask for the COFEPRIS health notice number and the advertising notice number, in writing.
• Verify the treating physician's *cédula profesional* in the SEP public registry.
• Confirm the legal name, RFC (tax ID), and address on the regulatory page match what is published on the clinic's website.
• Ask which Mexican Official Standards (NOMs) the clinic operates under and how clinical records are maintained.
• Ask whether peptides or compounded preparations come from a *farmacia magistral* with its own COFEPRIS license.
• Ask how the clinic handles pharmacovigilance and adverse event reporting.
• Ask for the channels available to file a complaint, including the path through COFEPRIS Citizen Services and CONAMED.

A clinic that answers each of these questions specifically, in writing, and without defensiveness is a clinic that takes the regulatory framework seriously. That is the kind of clinic worth considering.

Closing thoughts

Regulation is not bureaucracy for its own sake. It is the structure that makes accountability possible, and for an international patient making decisions from another country, it is one of the most reliable signals of seriousness a clinic can offer. COFEPRIS is a real federal authority with a real mandate, and the clinics that operate within its framework are the ones that can be inspected, verified, and held to a standard.

If you are evaluating regenerative medicine in Mexico, we encourage you to verify any clinic you are considering, including ours. Our COFEPRIS notice numbers are 2323025036X00098 (health notice) and 2323022002A00053 (advertising notice), our full regulatory information is published at /en/legal/regulatorio, and our medical team credentials are available on the team page. When you are ready to discuss your case, schedule a consultation and we will walk you through every question, including the regulatory ones, before any decision is made.